Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AN4035

Antibody-drug conjugate · Cytotoxic, directed at CEACAM5 · developed by Adlai Nortye Biopharma Co.

Phase 1 Most advanced trial

ANL Developer

1 Registered trials

What is AN4035?

AN4035 is an antibody-drug conjugate that targets CEACAM5 and is designed to deliver a pan-RAS(ON) inhibitor payload to tumor cells. It is being studied in solid tumors with RAS mutations and CEACAM5 expression.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: CEACAM5, RAS (secondary target)
Mechanism: Cytotoxic, directed at CEACAM5
Therapy area: Oncology
Developer: Adlai Nortye Biopharma Co., Ltd. (ANL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07686445	Phase 1	Solid Tumor (Phase I)	Not yet recruiting	ANL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CEACAM5RAS MutationSolid Tumor (Phase I)

More from Adlai Nortye Biopharma Co.

AN4005 Phase 1 AN8025 Phase 1 AN9025 Phase 1 Palupiprant Phase 1

Sources

ClinicalTrials.gov NCT07686445

Updated Oct 11, 2026. Something wrong or missing? Report it on the ANL page.

Follow ANL, the company behind AN4035

See ANL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z